We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.65%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.9B
AUM Growth
-$2.32B
(-3%)
Cap. Flow
-$2.03B
Cap. Flow
% of AUM
-2.75%
Top 10 Holdings %
Top 10 Hldgs %
22.54%
Holding
3,088
New
92
Increased
1,359
Reduced
1,564
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$60.7M |
| 2 |
Analog Devices
ADI
|
+$46.1M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$37.3M |
| 4 |
Match Group
MTCH
|
+$28.2M |
| 5 |
GXO Logistics
GXO
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$89.3M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$78.9M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$77.4M |
| 4 |
Apple
AAPL
|
+$77M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$70.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 14.2% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 12.09% |
| 5 | Communication Services | 9.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RETA
1651
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $3.06M | ﹤0.01% |
30,437
+268
| +0.9% | +$31.4K |
|
1652
WesBanco
WSBC
$4B
| $3.06M | ﹤0.01% |
89,715
+954
| +1% | +$31.6K |
|
1653
Sphere Entertainment
SPHR
$5.73B
| $3.05M | ﹤0.01% |
41,957
+12,890
| +44% | +$966K |
|
|
MFA
1654
MFA Financial
MFA
$933M
| $3.05M | ﹤0.01% |
166,623
+4,350
| +3% | +$80.8K |
|
1655
Extreme Networks
EXTR
$3.15B
| $3.04M | ﹤0.01% |
308,780
-47,763
| -13% | -$504K |
|
1656
Editas Medicine
EDIT
$442M
| $3.04M | ﹤0.01% |
73,871
+1,681
| +2% | +$92.1K |
|
1657
Phreesia
PHR
$773M
| $3.03M | ﹤0.01% |
49,039
+11,434
| +30% | +$763K |
|
|
FOLD
1658
DELISTED
Amicus Therapeutics
FOLD
| $3.02M | ﹤0.01% |
316,281
+7,018
| +2% | +$71.8K |
|
|
FOCS
1659
DELISTED
Focus Financial Partners Inc. Class A
FOCS
| $3.02M | ﹤0.01% |
57,579
+14,233
| +33% | +$727K |
|
1660
Donnelley Financial Solutions
DFIN
$1.16B
| $3.01M | ﹤0.01% |
86,988
-11,964
| -12% | -$395K |
|
1661
Atea Pharmaceuticals
AVIR
$420M
| $3M | ﹤0.01% |
85,692
+3,596
| +4% | +$99.7K |
|
1662
Calix
CALX
$2.39B
| $3M | ﹤0.01% |
60,750
+2,037
| +3% | +$93.9K |
|
1663
Scholastic
SCHL
$792M
| $3M | ﹤0.01% |
84,109
-13,620
| -14% | -$466K |
|
1664
Rush Enterprises Class A
RUSHA
$6.22B
| $2.99M | ﹤0.01% |
99,282
+2,685
| +3% | +$79.4K |
|
1665
Chefs' Warehouse
CHEF
$4.5B
| $2.98M | ﹤0.01% |
91,371
-11,549
| -11% | -$339K |
|
|
AXNX
1666
DELISTED
Axonics, Inc. Common Stock
AXNX
| $2.97M | ﹤0.01% |
45,693
+3,687
| +9% | +$252K |
|
1667
Hyatt Hotels
H
$16.7B
| $2.97M | ﹤0.01% |
38,564
-2,249
| -6% | -$170K |
|
1668
Shift4
FOUR
$3.26B
| $2.97M | ﹤0.01% |
38,335
-145
| -0.4% | -$12.5K |
|
|
SASR
1669
DELISTED
Sandy Spring Bancorp Inc
SASR
| $2.97M | ﹤0.01% |
64,821
+1,531
| +2% | +$65.6K |
|
1670
Kadant
KAI
$3.99B
| $2.97M | ﹤0.01% |
14,548
+389
| +3% | +$76.7K |
|
|
TBI
1671
Trueblue
TBI
$311M
| $2.96M | ﹤0.01% |
109,353
-13,579
| -11% | -$363K |
|
1672
Vanda Pharmaceuticals
VNDA
$302M
| $2.94M | ﹤0.01% |
171,309
-20,415
| -11% | -$358K |
|
1673
Domo
DOMO
$184M
| $2.93M | ﹤0.01% |
34,723
+2,964
| +9% | +$254K |
|
1674
CTS Corp
CTS
$1.89B
| $2.93M | ﹤0.01% |
94,796
-11,867
| -11% | -$406K |
|
|
MAXR
1675
DELISTED
Maxar Technologies Inc. Common Stock
MAXR
| $2.92M | ﹤0.01% |
103,259
+1,657
| +2% | +$53.2K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2021 Portfolio in Review
As of Q3 2021, RhumbLine Advisers held 3,088 positions worth $73.9B, down 3% from $76.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 4.5%. RhumbLine Advisers opened 92 new positions and exited 46, leaving the 3,088-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2021 buy was GXO Logistics: 250,722 shares worth $19.7M.
- RhumbLine Advisers added most to Moderna in Q3 2021, an estimated $60.7M increase.
- RhumbLine Advisers's biggest Q3 2021 reduction was Microsoft, cutting an estimated $89.3M.
- RhumbLine Advisers fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $77.4M.
- RhumbLine Advisers's ten largest holdings make up 23% of its $73.9B portfolio in Q3 2021.
- RhumbLine Advisers opened 92 new positions and closed 46 in Q3 2021.
- RhumbLine Advisers's portfolio value fell 3% quarter-over-quarter to $73.9B.
Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.